Biosciences
Our researchers in have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
-
Automating chemical drug discovery and synthesis
SRI International’s continuous flow SynFini™ Suite produced multiple nucleoside antivirals in a single day.
-
Intracellular delivery—now a reality for many types of therapeutics
Unlocking the therapeutic potential of antisense oglionucleotides and other biologics.
-
Making Distributed Teams More Connected
AI-powered discussion highlights to share knowledge with remote team members.
-
Partnering to Rapidly Advance ZMappTM for Ebola Treatment
SRI scientists partner with Mapp Biopharmaceutical to accelerate FDA approval for clinical trials.
-
HOPO: Partnering to Advance Therapy for Radiation Exposure
SRI scientists collaborate with Lawrence Berkeley National Laboratory to chart a path for obtaining regulatory approval for a clinical development plan for a novel decorporation agent.
-
EcoCyc: Encyclopedia of E. coli genes and metabolism
A bioinformatics database that describes the genome, metabolic network and regulatory network of Escherichia coli.
-
BioCyc database collection
A comprehensive website for sharing fundamental information about biochemical pathways and genomes with researchers around the world
-
Techneins™ – Non-natural polymers as synthetic affinity reagents and novel therapeutics
SRI Biosciences has developed a molecular discovery platform that enables the synthesis and screening of sequence-defined non-natural polymers, or “Techneins™”, to create potent and selective affinity reagents that can be used as either therapeutics or diagnostic reagents.
-
SynFini™
SRI Biosciences has developed SynFini™, a suite of tools that leverages AI to automate the translation of ideas into testable physical molecules.The SynFini platform helps scientists maximize time spent on what to make, rather than how to make by accelerating chemistry design, developme
-
FOX Three Molecular Guidance System (MGS)™
SRI Biosciences has developed the FOX Three Molecular Guidance System™ platform to deliver any cargo to selected cell types, then internalize into those cells to targeted subcellular locations.
-
Ian Colrain talks about SRI Biosciences
Ian Colrain is the former President of SRI’s Biosciences Division in Menlo Park, CA. Join us to learn how SRI Biosciences partners with organizations worldwide to bring new medicines and devices to market through basic research, pharmaceutical and technology discovery, preclinical development and clinical translation. provides services that span all stages of drug and diagnostics…
-
Mary Lanier talks about SRI Biosciences’ response to the ongoing COVID-19 pandemic
Mary Lanier is a Research Scientist at SRI Biosciences in Menlo Park, CA. Join us to learn how SRI Biosciences is responding to the COVID-19 pandemic—from using existing drug discovery and delivery platforms to innovate vaccines and treatment, to rapid testing capabilities, to developing new vaccines that could protect against future viruses. Learn more about…